


August 19, 2024

MEMORANDUM

No. 2024- 0070

TO : **ALL CONCERNED END-USERS**
PhilHealth Regional Office 8

FROM : 
RONALD S. JABAY
Regional Vice-President

SUBJECT : **Approval of CY 2024 Annual Procurement Plan (APP)**
Amendment (16th Batch)

The Corporation has approved its CY 2024 Annual Procurement Plan (APP) for the implementation of its various programs/projects to further fulfill its mandate of providing universal, affordable and equitable health care for all Filipinos.

To reflect, however, the necessary adjustments brought about by factors beyond reasonable planning such as but not limited to extraordinary fluctuations in prices, introduction of new projects, activities, and programs in the original CY 2024 APP, the same should be updated and/or amended.

After judicious review and evaluation, the requested revisions/modifications in programs and projects by end-users were deemed significant and necessary for the effective and efficient delivery of public service by the Corporation.

Pursuant to the following provisions under the 2016 Revised Implementing Rules and Regulations of Republic Act No. 9184, otherwise known as the "Government Procurement Reform Act of 2003", the CY 2024 APP is hereby amended:

"Section 7.2 No procurement shall be undertaken unless it is in accordance with the approved APP, including approved changes thereto. The APP must be consistent with the duly approved yearly budget of the Procuring Entity and shall bear the approval of the HoPE or second-ranking official designated by the HoPE to act on his behalf.

Section 7.4 Changes to the individual PPMPs and the consolidated APP may be undertaken every six (6) months or as often as may be required by the HoPE."

MASTER
COPY
DATE: 8/20/24
DC: [Signature]

Accordingly, and under the authority granted by the PhilHealth Board of Directors to the Regional Vice President as Head of the Procuring Entity, this Memorandum is hereby issued approving the attached CY 2024 Annual Procurement Plan (APP) Amendment (16th Batch)

It is emphasized that all procurement based on the approved CY 2024 APP and its amendments must be undertaken strictly in accordance with the terms, conditions and requirements provided in the law, its Revised IRR as well as relevant government and corporate procurement policies, rules and regulations, subject to usual government auditing and accounting rules and regulations.

For the information and strict compliance of all concerned.



RESOLUTION No.08-200

s. 2024

BAC Resolution Recommending the Approval of the CY 2024 Annual Procurement Plan (APP) Amendment (16th Batch) – Including the Method of Procurement of Activities/Projects

WHEREAS, Section 7.4 of the Revised Implementing Rules and Regulations of RA 9184 provides for the updating of the Annual Procurement Plan (APP) which states that:

“Sec. 7.4 Updating of the individual PPMPs and the consolidated APP for each procuring entity shall be undertaken every six (6) months or as often as may be required by the Head of the Procuring Entity. The updating of the PPMPs shall be the responsibility of the respective end-user units of the Procuring Entity, while the consolidation of these PPMPs into an APP shall be lodged with the BAC Secretariat, subject to the approval of the Head of the Procuring Entity.”

WHEREAS, based on the above provision, the submitted Project Procurement Management Plan (PPMP) for various projects and activities were consolidated by the Secretariat for the Bids and Awards Committee (SBAC) of PRO 8 for the updating of the Annual Procurement Plan (APP) – 16th Batch;

WHEREAS, upon consolidation of the PPMPs into the amended APP, the PRO 8-SBAC indicated the proposed method of procurement for each program/project/activity thereat;

WHEREAS, on 19th of August 2024, the BAC through a meeting, reviewed the proposed amendments including the appropriate method of procurement;

NOW, THEREFORE, premises considered, the PhilHealth Regional Office No. 8 Bids and Awards Committee (PRO- 8 BAC), pursuant to Section 7.4 of the Revised IRR of RA 9184, hereby recommends to the Regional Vice President the approval of the attached proposed CY 2024 Annual Procurement Plan (APP) Amendment (16th Batch);

Actual procurement for programs, projects and activities in the 2024 APP Amendment (16th Batch) to be undertaken through any of the alternative methods must strictly comply with the requirements and procedures under the Revised Implementing Rules and Regulations of Republic Act No. 9184, as well as other relevant government and corporate procurement policies, standards, rules and regulations.

IT IS SO RESOLVED.

MASTER
COPY

OC:

DATE:

9/2/24

Signed this 19th day of August 2024, at the City of Tacloban.


ACISCLO B. MILITANTE, JR.
BAC Chairperson


ATTY. ALFREDO B. TY, JR.
BAC Member


DR. MARY GRACE J. LABINE
BAC Member


MELVIN S. ZABALA
BAC Member


RICHARD MAURO R. BUGHO
Alternate BAC Member

☒ **APPROVED**
☐ **DISAPPROVED**


RONALD S. JABAY
Regional Vice-President

Date Signed: 7/02/24

MASTER
COPY

DC:

DATE:



Republic of the Philippines
PHILIPPINE HEALTH INSURANCE CORPORATION
PhilHealth Regional Office VIII
167 Padre Burgos St., Tacuban City, Leyte, 6500
(053) 523-8285 • www.philhealth.gov.ph
PhilHealthRegions • @ourphilhealth

ANNUAL PROCUREMENT PLAN (APP) CY 2024
AMENDMENT (16th Batch)
BAC - GOODS AND SERVICES (MOOE)

Code (PAP)	Procurement Program/Project	PMO/ End-User	Mode of Procurement	Schedule for Each Procurement Activity				Source of Funds				Remarks (Brief description of Programs/Project)
				Ads/Post of IB/REI	Sub/Open of Bids	Notice of Award	Contract of Signing		Total	MOOE	CO	
	TOPICAL ANTIBACTERIAL: AREA3: Mupirocin Ointment 5g	MSD-ASS-HRU	NP-Small Value Procurement					COB	10,914.75	10,914.75		To reflect in the CY 2024 APP the adjusted budget due to increase in quantity
	PENICILLINS: AREA3: Cloxacillin 500mg	MSD-ASS-HRU	NP-Small Value Procurement					COB	793.80	793.80		
	PAIN RELIEVER: AREA3: Celecoxib 400mg	MSD-ASS-HRU	NP-Small Value Procurement					COB	1,267.88	1,267.88		
	ORAL ANTISPASMODIC: AREA3: Hyoscine-N Butylbromide 10 mg	MSD-ASS-HRU	NP-Small Value Procurement					COB	1,700.61	1,700.61		
	NSAIDS: AREA3: Metenamic Acid 500 mg	MSD-ASS-HRU	NP-Small Value Procurement					COB	413.44	413.44		
	NSAIDS: AREA3: Ibuprofen 500 mg	MSD-ASS-HRU	NP-Small Value Procurement					COB	1,515.94	1,515.94		
	NASAL DECONGESTANTS: AREA3: Sodium Chloride, Drops for colds/nasal congestion, 60 ml	MSD-ASS-HRU	NP-Small Value Procurement					COB	6,662.50	6,662.50		
	COUGH AND COLD PREPARATIONS: AREA3: Vitex Negundo L. Lagundi Leaf, 600 mg	MSD-ASS-HRU	NP-Small Value Procurement					COB	1,791.56	1,791.56		
	ANTVERTIGO: AREA3: Betahistine Dihydrochloride, 16mg	MSD-ASS-HRU	NP-Small Value Procurement					COB	1,736.44	1,736.44		
	ANTIPTYRETICS: AREA3: Paracetamol 500mg	MSD-ASS-HRU	NP-Small Value Procurement					COB	482.35	482.35		
	ANTIHYPERTENSIVE: AREA3: Losartan Potassium, 50mg	MSD-ASS-HRU	NP-Small Value Procurement					COB	752.43	752.43		
	ANTVERTIGO: AREA3: Clonidine Hydrochloride, 17mg	MSD-ASS-HRU	NP-Small Value Procurement					COB	4,465.13	4,465.13		
	ANTIHYPERTENSIVE: AREA3: Amlodipine Besilate, 10mg	MSD-ASS-HRU	NP-Small Value Procurement					COB	926.10	926.10		
	ANTIHISTAMINE (Parenteral): AREA3: Diphenhydramine Chloride	MSD-ASS-HRU	NP-Small Value Procurement					COB	305.55	305.55		
	ANTIHISTAMINE: AREA3: Loratidine 10 mg	MSD-ASS-HRU	NP-Small Value Procurement					COB	694.58	694.58		
	ANALGESICS (Oral): AREA3: Metoprolol 10 mg	MSD-ASS-HRU	NP-Small Value Procurement					COB	275.63	275.63		
	ANTIDARRHEALS: AREA3: Loperamide 2 mg	MSD-ASS-HRU	NP-Small Value Procurement					COB	330.75	330.75		

MASTER COPY
DATE 9/24

Code (PAP)	Procurement Program/Project	PMO/ End-User	Mode of Procurement	Schedule for Each Procurement Activity					Source of Funds				Remarks (Brief description of Programs/Project)
				Ads/Post of IB/REI	Sub/Open of Bids	Notice of Award	Contract Signing			Total	MOOE	CO	
	ANTIBIOTICS: AREA3: Doxycycline 100 mg	MSD-ASS-HRU	NP-Small Value Procurement						COB	479.59	479.59		To reflect in the CY 2024 APP the adjusted budget due to increase in quantity
	ANTIBIOTICS: AREA3: Amoxicillin 500 mg	MSD-ASS-HRU	NP-Small Value Procurement						COB	689.06	689.06		
	ANTI-ASTHMATIC: AREA3: Salbutamol	MSD-ASS-HRU	NP-Small Value Procurement						COB	99.23	99.23		
	ANTI-ANGINAL: AREA3: Isosorbide Dinitrate 5mg	MSD-ASS-HRU	NP-Small Value Procurement						COB	1,102.50	1,102.50		
	ANTI-ANGINAL: AREA3: Isosorbide Dinitrate 10mg	MSD-ASS-HRU	NP-Small Value Procurement						COB	866.25	866.25		
	ANTACIDS: AREA3: Omeprazole 20 mg	MSD-ASS-HRU	NP-Small Value Procurement						COB	810.34	810.34		
	ACE INHIBITORS: AREA3: Captopril 25 mg	MSD-ASS-HRU	NP-Small Value Procurement						COB	438.25	438.25		
	Training on FMS Staff & Designates (two-day activity)	MSD-ASS-HRU	NP-Lease of Real Property and Venue						COB	108,000.00	108,000.00		
TOTAL										147,514.66	147,514.66		

Prepared by:

Recommending Approval:


MELVIN S. ZARALA
 BAC Member


DR. MARY GRACE J. LABINE
 BAC Member

BIDS AND AWARDS COMMITTEE (BAC)


LAWRENCE A. DIDULO
 SIO II/Head, SBAC


ATTY. ALFREDO H. TY, JR.
 BAC Member

Approved by:


RONALD D. JABAY
 Regional Vice President


RICHARD M. ROD R. BUGHO
 Alternate BAC Member


ACISCIO P. MILTANTE, JR.
 BAC Chairperson

MASTER COPY
 DATE: 9/10/24